Saegis Pharmaceuticals


Public lists: Pharma Startups (4732)

Saegis Pharmaceuticals is a leader in the development of next generation medicines to improve memory and cognition deficits associated with human Central Nervous System (CNS) diseases. As the first company devoted to developing therapeutics to preserve and enhance the human mind, Saegis is focused on providing a new standard of care for patients suffering from debilitating diseases. Saegis has three small molecule drugs in late preclinical and clinical development and has a growing pipeline of n...Show all

Saegis Pharmaceuticals is a leader in the development of next generation medicines to improve memory and cognition deficits associated with human Central Nervous System (CNS) diseases. As the first company devoted to developing therapeutics to preser...Show all

Company (Acquired)

Phone: 650-560-0210

Fax:

60 Stone Pine Road
Suite 200
Half Moon Bay, 94019
California, United States

Latest News

See more competitors data Competitors
Total Funding Date of Last Funding
Saegis Pharmaceuticals $63.5M Dec 20, 2006
See all 64 competitors

Web Traffic

Rank

Show (-10)

Engagement (PVPU)

Show (+1%)

Domain Authority Score
Show
Page Views Per Million (PVPM)
Show
Reach Per Million
Show

SEO Statistics

Domain Authority Score Show
Page Authority Score Show
No. External Links Show
No. Links Show

Web Traffic Statistics - Growth

Per Week Per Month Per 6 Months Per Year
Rank Login to see details
Page Views Per Million Login to see details
Page Views Per User Login to see details
Reach Per Million Login to see details

Related Saegis Pharmaceuticals Jobs

jobs by Indeed job
						search

Investors

Investor Investor Type Location Participating Rounds
See all 8 investors
There is no Board of Directors data available for this company. Please select another tab.

Competitors

Company Status Description Investors

Targacept

Winston-Salem, North Carolina, United States
IPO / Went publicTargacept is a biopharmaceutical company advancing NNR Therapeutics for the treatment of various diseases and disorders. The company's NNR Therapeutics selectively target neuronal nicotinic receptors, or NNRs. NNRs are found on nerve cells throughout the nervous system and serve as key regulators of nervous system activity.Login to see details

Morphotek

Exton, Pennsylvania, United States
AcquiredInformation about Eisai pharmaceuticals prescription drugs Aricept, Cerebyx, Zonegran, Fragmin and Aciphex used for treatment of Alzheimer's disease and neurology disorders, peptic ulcers, GERD and nighttime heartburn, status epilepticus, epilepsy and prevention of deep-vein thrombosis (DVT).Login to see details
See all 64 competitors

Patents

Title Application Date Patent Date Status
(Patent / Application)